UPM Pharmaceuticals, a CDMO focused on solid oral and semi-solid dosage forms, has appointed Chris Curtin as chief operating officer. This comes as a promotion from his previous role as executive vice president of Quality Operations. Mr. Curtin will lead the organization responsible for Research & Development, Manufacturing, Quality Assurance, Inventory Management, Quality Control and Analytical Services.

Jim Gregory, chief executive officer of UPM Pharmaceuticals, stated “Chris brings a tremendous amount of industry experience and expertise.  We feel strongly that Chris is perfectly positioned to lead UPM into the next phase of growth. Chris has been instrumental in putting quality processes in place across the organization and we are confident that under his guidance, UPM will continue to grow and strive for excellence.”

Mr. Curtin has held executive management positions at Parke-Davis/Warner Lambert, King Pharmaceuticals, Graceway Pharmaceuticals, Rockward Pharmaceutical Consultants, Actient Pharmaceuticals and more recently Lynwood Pharmaceuticals. 

“In my role as COO I look forward to enhancing UPM’s presence and marketability in the CDMO space by utilizing the talents and technical skills of all our UPM colleagues to enhance systems, processes and capabilities,” Mr. Curtin said.